GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » EBIT per Share

Eyenovia (Eyenovia) EBIT per Share : $-0.69 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eyenovia EBIT per Share?

Eyenovia's EBIT per Share for the three months ended in Mar. 2024 was $-0.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.69.

During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Eyenovia's EBIT per Share or its related term are showing as below:

EYEN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -61.8   Med: -4.55   Max: 35.2
Current: 13

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Eyenovia was 35.20% per year. The lowest was -61.80% per year. And the median was -4.55% per year.

EYEN's 3-Year EBIT Growth Rate is ranked better than
62.37% of 1302 companies
in the Biotechnology industry
Industry Median: 3.55 vs EYEN: 13.00

Eyenovia's EBIT for the three months ended in Mar. 2024 was $-10.24 Mil.


Eyenovia EBIT per Share Historical Data

The historical data trend for Eyenovia's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia EBIT per Share Chart

Eyenovia Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only -1.47 -0.94 -0.47 -0.79 -0.61

Eyenovia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.15 -0.17 -0.15 -0.22

Eyenovia EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Eyenovia's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-24.889/41.033
=-0.61

Eyenovia's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

EBIT per Share(Q: Mar. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-10.243/46.607
=-0.22

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eyenovia  (NAS:EYEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Eyenovia EBIT per Share Related Terms

Thank you for viewing the detailed overview of Eyenovia's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Eyenovia (Eyenovia) Business Description

Traded in Other Exchanges
N/A
Address
295 Madison Avenue, Suite 2400, New York, NY, USA, 10017
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Executives
Michael M Rowe director, officer: Chief Executive Officer C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Ellen R Strahlman director ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Stuart M. Grant 10 percent owner 11 SUMMIT LANE, GREENVILLE DE 19807
Ram Palanki director C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson director C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo officer: Chief Financial Officer 62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern officer: Chief Operating Officer 295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev director 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin director 135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401